- Blog
- Research & Benefits
Category
Research & Benefits
What studies show about GLP-1 medicines beyond weight, from heart and kidneys to sleep apnea, with the limits spelled out.
Research & BenefitsAverage Weight Loss vs Responder Rates: Two Different Trial Results
'Average 15% weight loss' and 'half lost at least 15%' describe the same trial in two different ways. Here's how to read both, using real STEP 1, SURMOUNT-1 and ATTAIN-1 numbers.
Research & BenefitsConfidence Intervals in GLP-1 Studies, Explained Without the Math
That little range in parentheses after a GLP-1 result is the most honest number in the paper. Here is how to read it in three steps, using real Wegovy and Zepbound trial results.
Research & BenefitsConflicts of Interest in GLP-1 Research: What a Disclosure Means
Almost every big GLP-1 trial was paid for by the company that makes the drug. That's normal, and it still matters. Here's how to read a disclosure without either panicking or shrugging.
Research & BenefitsGLP-1 and Oral Health Research: What Scientists Are Finding
Researchers are looking at GLP-1 medicines and the mouth from two directions: possible problems like dry mouth and erosion, and possible benefits for gums. Here is what the studies actually show so far.
Research & BenefitsGLP-1 Clinical Trial Eligibility: Who Gets Left Out and Why
Every GLP-1 trial has a guest list. Here is who was usually not on it, why researchers draw the lines, and what that means when you read a headline about people who may not look like you.
Research & BenefitsGLP-1 Extension Studies: What Happens After a Trial Ends
When the main trial ends, the story is not over. Here are the three kinds of GLP-1 follow-up studies, what each one can prove, and the fine print that changes how to read them.
Research & BenefitsGLP-1 Headline Quiz: Fact, Spin or Missing Context?
Ten news-style GLP-1 headlines, three possible verdicts and the real numbers behind each one. Can you tell a fact from a spin from a headline that left out the important part?
Research & BenefitsGLP-1 Microdosing: Why It's Trending and What the Evidence Says
Microdosing GLP-1s is all over social media, but there is still no clinical trial behind it. Here is what the first real-world data shows, what the labels say about low doses, and what to ask instead.
Research & BenefitsGLP-1 Trial Dropouts and Missing Data: Why Two Numbers Appear
Why did the same GLP-1 pill trial report 12.4% in a press release and 11.2% in the journal? Dropouts. Here's what estimands are, in plain words, and what to check.
Research & BenefitsGLP-1 Trial Duration: What 68, 72 and 176 Weeks Can Tell You
A 68-week trial and a three-year trial can study the same drug and still answer different questions. Here is what each timeline can, and cannot, tell you about long-term GLP-1 use.
Research & BenefitsGLP-1 Trial Endpoints Explained: Primary, Secondary and MACE
The endpoint is the question a trial promised to answer. Learn the difference between primary, secondary, composite and surrogate endpoints using the actual GLP-1 trials behind today's labels.
Research & BenefitsGLP-1 Trial Subgroup Analysis: When a Promising Chart Misleads
A trial once found aspirin didn't help Geminis and Libras. Here's why GLP-1 subgroup charts deserve the same raised eyebrow, and how to read a forest plot in two minutes.
Research & BenefitsHow to Read a GLP-1 Study Headline in Five Minutes
A five-minute, five-question routine for any GLP-1 headline, tested on real trials like SELECT and ATTAIN-1. No statistics degree, just a timer and some healthy suspicion.
Research & BenefitsIs This GLP-1 Claim Peer-Reviewed? How to Check in 4 Steps
Press release, conference abstract, preprint or journal paper? Each one tells you something different about a GLP-1 claim. Here's how to tell them apart and check for retractions.
Research & BenefitsKFF 2026 Employer Survey: GLP-1 Coverage Numbers, Explained
KFF's 2026 Employer Health Benefits Survey, published October 22, asked large employers whether they cover GLP-1s for weight loss, what they require and how the cost is hitting them. Here are the actual numbers and what they mean for workers.
Research & BenefitsPlacebo-Controlled GLP-1 Trials: What They Tell Us (and Don't)
Placebo groups in GLP-1 trials lose weight, report stomach trouble and sometimes quit. Here's what that comparison proves, and the questions it leaves open.
Research & BenefitsReal-World Data vs Randomized Trials: Why GLP-1 Research Needs Both
Trials tell us what a GLP-1 can do under ideal conditions. Health-record studies show what happens with copays, shortages and busy lives. Here's what each is good for, with real examples.
Research & BenefitsRelative vs Absolute Risk: The GLP-1 Headline Math to Know
A 20% drop and a 1.5-point drop can be the same result. Here is the simple math behind GLP-1 headlines, using real SELECT and STEP 1 numbers for both benefits and side effects.
Research & BenefitsWhy GLP-1 Studies Disagree: Same Drug, Different Results
Semaglutide 2.4 mg produced -14.9% in one trial and -9.6% in another. Neither was wrong. Here are the six reasons GLP-1 studies disagree, and how to compare them fairly.
Research & BenefitsGLP-1s, Gut Microbiome, and Pain: What We Know So Far
Emerging research suggests a link between GLP-1 medicines, the gut microbiome, and chronic pain relief. Here’s what current science and clinical reports reveal.
Research & BenefitsCan GLP-1 Medicines Reduce Diabetes Complications? Evidence Depends on the Drug
Some GLP-1 medicines have evidence for specific heart or kidney outcomes in type 2 diabetes. Why the drug, the patient group and the label all matter.
Research & BenefitsCan GLP-1 Treatment Lower Blood Pressure? What to Know
Semaglutide and tirzepatide trials report lower average blood pressure, but effects vary. Learn what studies show and why medicine changes need your clinician.
Research & BenefitsCould GLP-1 Medicines Affect Alcohol Cravings? The Research Is Early
Small randomized trials suggest semaglutide may reduce some drinking outcomes, but GLP-1s aren't approved for alcohol use disorder. Here's what trials found.
Research & BenefitsDoes GLP-1 Treatment Improve Quality of Life? What Studies Measure
Clinical trials measure more than weight. How researchers assess physical function and quality of life in GLP-1 studies, and what those results can't tell you.
Research & BenefitsGLP-1 Drugs and Smoking: What Researchers Are Investigating
Small trials have tested GLP-1 drugs for smoking, with mixed results. They aren't approved quit-smoking treatments. Here's what the evidence shows so far.
Research & BenefitsGLP-1 Medication and Fertility: What Changes May Mean
Weight and metabolic changes can affect cycles, but GLP-1 medicines aren’t fertility treatments. What evidence shows and why pregnancy plans need a talk first.
Research & BenefitsGLP-1 Medicines and Dementia: Why Observational Studies Are Not Proof
Observational studies link GLP-1 medicines to lower dementia risk, but the first big Alzheimer’s trials of semaglutide found no benefit. How to read it.
Research & BenefitsGLP-1 Medicines and Heart Failure: Why the Specific Trial Matters
STEP-HFpEF and SUMMIT tested semaglutide and tirzepatide in people with obesity and HFpEF. Learn what each found, what they didn't show, and US label status.
Research & BenefitsGLP-1 Medicines and Knee Osteoarthritis: What We Know About Pain and Mobility
STEP 9 tested semaglutide in adults with obesity and knee osteoarthritis. See what changed in pain and function over 68 weeks, and why the result has limits.
Research & BenefitsGLP-1 Medicines and PCOS: What Evidence Exists So Far?
Small trials suggest GLP-1 medicines may help some PCOS markers, but evidence on fertility is thin. What's known, what isn't, and why pregnancy plans matter.
Research & BenefitsGLP-1 Medicines and Prediabetes: What Trials Can Tell Us
A 3-year tirzepatide trial cut progression to type 2 diabetes in adults with obesity and prediabetes. Learn what it showed, its limits, and questions to ask.
Research & BenefitsGLP-1 Medicines, Perimenopause and Menopause: What Is Known So Far?
Midlife weight changes can overlap with menopause and GLP-1 treatment. What's established, what's still early, and what to discuss with a clinician.
Research & BenefitsGLP-1, Inflammation and Metabolic Health: Separating Mechanism From Outcomes
GLP-1 trials show lower inflammation markers like CRP, but a marker change doesn’t prove a medicine treats inflammatory disease. Here’s how to read the claims.
Research & BenefitsGLP-1s and Sleep: What Is Known Beyond Sleep Apnea
Some people sleep better on GLP-1s, others worse. Evidence differs for sleep apnea, general sleep quality and everyday tiredness. Here’s how to tell them apart.
Research & BenefitsSemaglutide and Fatty Liver Disease (MASH): What the Research Shows
Wegovy has US accelerated approval for MASH with F2–F3 fibrosis. See what the ESSENCE trial found at 72 weeks, who it applies to, and why follow-up matters.
Research & BenefitsSemaglutide and Kidney Disease: What the FLOW Trial Found
FLOW tested semaglutide in adults with type 2 diabetes and kidney disease. Learn what it found, what Ozempic's US kidney indication covers, and what it doesn't.
Research & BenefitsTirzepatide for Sleep Apnea: Who the Evidence Applies To
Zepbound is US-approved for moderate-to-severe sleep apnea in adults with obesity. See what SURMOUNT-OSA found, who was studied and why CPAP still matters.
Research & BenefitsWegovy and Heart Health: What the SELECT Trial Actually Found
SELECT tested semaglutide 2.4 mg in adults with overweight or obesity and heart disease. Here's what it found, in absolute and relative terms, and who it fits.
Make your GLP-1 journey easier to track 💚
Keep your shots, weight, food, water and symptom notes together with GLPily, and meet Pily, the little coach who answers from your own logs.
- Shot tracking
- Water & symptoms
- Weight trends
- Journal
- Food scanner
- Progress photos